Dr. Lionel Low, Head of Research at Tikva Allocell, delivered a compelling keynote at the 3rd Cell and Gene Therapy R&D Congress Asia by Global Engage.
Tikva Allocell announces that CEO and Founder, Ivan Horak, will speak at the 3rd Clinical Trial Festival Asia 2025 in Singapore, organized by IMAPAC.
Dr. Ivan D. Horak, CEO and Founder of Tikva Allocell (Tikva), received the Lifetime Achievement Award at APCGTEA 2024 in recognition for his contributions and leadership in the cell and gene therapy.
Tikva Allocell was one of the top 6 finalist companies of the Amgen x NSG BioLabs Golden Ticket Award.
We are pleased to announce our upcoming presentation at the 2nd Singapore Innovation and Enterprise Showcase happening alongside the JP Morgan Healthcare Conference in SF.
We are invited to the highly anticipated JP Morgan Healthcare
Conference in January 8-11, 2024 at San Fransisco, California. We hope to meet you there!
Our CEO and co-founder, Ivan D. Horak, moderated a panel discussion on “Innovations and Opportunities in Cell and Gene therapy in the APAC region” at the 7th annual Cell and Gene Therapy World Asia 2023 conference (Singapore). This event showcased the dynamic and rapidly evolving Cell & Gene Therapy industry in the Asia-Pacific region.